Please assess the completion status of the following clinical trial:

Trial Title: Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 or ≤ 75 years~* Patients with rhegmatogenous retinal detachment that require vitrectomy surgery~Exclusion Criteria:~* Previous pars plana vitrectomy in the affected eye~* Positive for Hepatitis B surface antigen or HIV antibodies, or history of Hepatitis B/HIV~* Pregnant or breast-feeding~* Liver disease or abnormal AST/ALT~* Renal impairment (Creatinine clearance \< 50)~* Diabetes with current use of insulin~* Anemia (Hemoglobin \<13.2 g/dL (male) or \< 11.6 g/dL (female))~* Unwilling to hold concurrent use of sorbitol or sorbitol-containing medications or products while taking study medication(including, but not limited to: blackberries, raspberries, strawberries, stone fruits, apples, avocados, sugar-free items such as chewing gum, hard candies, snack bars, frozen desserts, and chocolates, liquid and capsule/caplet analgesics, cough/cold/flu syrup, liquid and capsule/caplet pseudoephedrine, chewable antacid tablets, liquid and capsule allergy medications, motion sickness and nausea medications)~* Current use of trimethoprim-sulfamethoxazole~* Pancreatitis or history of pancreatitis~* Uncontrolled blood pressure (\> 160 mm Hg systolic or \>100 mm Hg diastolic) within the last 3 months, or current use of more than one anti-hypertensive medication~* History of stroke, myocardial infarction, or congestive heart failure~* Current vitreous hemorrhage that obscures view of retinal details~* Patients with a shallow anterior chamber or in whom anterior chamber paracentesis is considered unsafe

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lamivudine (Type: EXPERIMENTAL): Lamivudine 300mg PO once daily for three days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once daily for three days

Based on this trial design, predict the completion outcome and termination type (if applicable).